Journal of Lipid Research (Oct 2015)

Protective associations of HDL with blood-brain barrier injury in multiple sclerosis patients

  • Kelly Fellows,
  • Tomas Uher,
  • Richard W. Browne,
  • Bianca Weinstock-Guttman,
  • Dana Horakova,
  • Helena Posova,
  • Manuela Vaneckova,
  • Zdenek Seidl,
  • Jan Krasensky,
  • Michaela Tyblova,
  • Eva Havrdova,
  • Robert Zivadinov,
  • Murali Ramanathan

Journal volume & issue
Vol. 56, no. 10
pp. 2010 – 2018

Abstract

Read online

The purpose of this work was to investigate the associations of serum cholesterol and apolipoproteins with measures of blood-brain barrier (BBB) permeability and CNS inflammation following the first clinical demyelinating event. This study included 154 patients [67% female; age, 29.5 ± 8.2 years (mean ± SD)] enrolled in a multi-center study of interferon β1-a treatment following the first demyelinating event. Blood and cerebrospinal fluid (CSF) were obtained at screening prior to treatment. A comprehensive serum lipid profile and multiple surrogate markers of BBB breakdown and CNS immune activity were obtained. Higher levels of serum HDL cholesterol (HDL-C) and ApoA-I were associated with lower CSF total protein level, CSF albumin level, albumin quotient, and CSF IgG level (all P ≤ 0.001 for HDL-C and all P < 0.01 for ApoA-I). HDL-C was also associated with CSF CD80+ (P < 0.001) and with CSF CD80+CD19+ (P = 0.007) cell frequencies. Higher serum HDL is associated with lower levels of BBB injury and decreased CD80+ and CD80+CD19+ cell extravasation into the CSF. HDL may potentially inhibit the initiation and/or maintenance of pathogenic BBB injury following the first demyelinating event.

Keywords